Global Ureteral Stent Industry Set for Significant Growth, Projected to Reach USD 616.8 Million by 2032

The global ureteral stent industry is on track for substantial growth, with projections forecasting a rise from USD 385.9 million in 2022 to an estimated USD 616.8 million by 2032. This represents a robust Compound Annual Growth Rate (CAGR) of 4.4% over the forecast period, underscoring the increasing demand for these critical medical devices.

Ureteral stents, which are finely engineered plastic tubes designed to facilitate urine flow through obstructed ureters, are gaining traction due to their effectiveness in treating a variety of urinary tract disorders. These conditions, which often require intervention to restore normal urinary function, are driving the demand for ureteral stents globally.

The growing preference for minimally invasive procedures, such as ureteral stenting, is propelling the market forward. Ureteral stents, placed within the ureters, ensure unobstructed urine flow by providing a vital connection between the kidney and the urinary bladder. This technology not only alleviates urinary blockages but also reduces recovery time and patient discomfort, making it an increasingly sought-after solution for both healthcare providers and patients.

In addition to rising demand, technological advancements in stent case management and patient safety interfaces are further accelerating market expansion. These innovations cater to the needs of healthcare professionals, providing enhanced tools for stent management and improving overall patient outcomes.

“The growing prevalence of urinary tract disorders underscores the significance of ureteral stents as indispensable medical devices,” commented an expert from FMI. “With continuous technological advancements and a strong shift towards minimally invasive interventions, the ureteral stent industry is poised for remarkable growth.”

As the global healthcare landscape continues to evolve, stakeholders in the ureteral stent industry are well-positioned to capitalize on emerging opportunities. This dynamic sector is set to witness groundbreaking innovations, enhancing treatment options and improving the quality of life for patients worldwide.

Ureteral Stent Market: Drivers and Restraints

Drivers:

  • Increasing Urological Procedures: The rise in the number of urological procedures is a significant driver for the ureteral stent industry. Factors such as sedentary lifestyles and an expanding elderly population contribute to this increase.
  • Demographic Factors: Factors like poor dietary habits, low fluid intake, increasing obesity levels, and a rising caseload of metabolic disorders contribute to the growth of the market by necessitating more urological interventions.
  • Technological Advancements: Advancements in stent composition materials, such as those aimed at minimizing patient discomfort, as well as innovations in mesh stent design and construction, contribute positively to market growth by enhancing patient outcomes and satisfaction.
  • Smartphone Applications: The availability of innovative smartphone applications for stent case management and patient safety has boosted market growth. These applications provide useful tools for both physicians and patients, improving overall care and management of ureteral stent cases.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

Restraints:

  • Complex Procedure: The complexity of stent placement procedures poses a significant restraint to market growth. This complexity can lead to challenges in adoption and utilization, particularly in regions with limited access to skilled surgeons and healthcare facilities.
  • Lack of Skilled Surgeons: A shortage of skilled surgeons specialized in ureteral stent placement and management acts as a restraint to market growth. This limitation can hinder the adoption of stent procedures and affect patient access to adequate care.
  • Complications and Discomfort: Complications following stent removal, as well as discomfort associated with living with a ureteral stent, are major restraints for market growth. Side effects such as increased frequency and urgency of urination can impact patient satisfaction and adherence to treatment.

Overall, while factors such as increasing urological procedures and technological advancements drive the growth of the ureteral stent market, challenges such as procedural complexity, shortage of skilled surgeons, and patient discomfort pose significant barriers to its expansion.

Key Companies Profiled:

  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • Cook Medical
  • BD
  • Coloplast Ltd.
  • Medline Industries
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • Teleflex Incorporated

Top of Form

Ureteral Stent Market: Segmentation

Based on the type, the global ureteral stent industry is segmented into:

  • Open end stents
  • Closed end stents
  • Double pigtail stents
  • Multiloop stents

Based on the composition material, the global ureteral stent industry is segmented into:

  • Polyurethane stents
  • Silicone stents
  • Hydrogel stents
  • Plastic stents
  • Metal stents
  • Coated Stents

Based on the application, the ureteral stent market is segmented into:

  • Lithotripsy
  • Ureterorenoscopy
  • Schistosomiasis

Based on the end user, ureteral stent industry is segmented into the following:

  • Hospitals
  • Gastrointestinal surgery clinics

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Pharmaceutical Sterility Testing Industry Set for Explosive Growth, Projected to Reach USD 3,815.6 Million by 2033

The global pharmaceutical sterility testing industry is on the brink of an extraordinary expansion, with forecasts predicting a meteoric rise from USD 1,250.7 million in 2023 to an impressive USD 3,815.6 million by 2033. This notable growth, driven by an 11.8% compound annual growth rate (CAGR), underscores the increasing demand for safe and effective medications amid a global surge in chronic diseases.

Sterility testing is a critical component in the pharmaceutical and biological industries, ensuring product safety and efficacy by identifying potential contamination risks throughout various production stages. This rigorous testing process is vital for protecting patients and maintaining high standards of healthcare.

This heightened demand underscores the industry’s commitment to rigorous safety standards, ensuring that all pharmaceutical products are free from viable contaminating microorganisms prior to their release into the market. The expansion of the sterility testing industry is indicative of a broader trend towards higher safety standards and quality assurance in the production of medical and pharmaceutical products.

As the pharmaceutical and healthcare sectors continue to evolve, the sterility testing market is poised to play an even more pivotal role in the development and deployment of safe medical treatments, contributing to the overall growth and expansion of the global healthcare industry.

Potential Market Opportunity:

An increase in research and development expenditures in the biopharmaceutical industry contributed to the market’s expansion. For instance, in December 2021, the pharmaceutical industry’s annual research and development spending was 7.3 times higher than that of the aerospace and defense industries. Moreover, it was 6.5 times higher than that of the chemicals industry and 1.5 times higher than that of the software industry.

Key Takeaways:

  • By 2033, the pharmaceutical sterility testing industry in the United Kingdom is likely to expand at a CAGR of 9.5%.
  • In 2022, the United States dominated the pharmaceutical sterility testing sector, with a share of 41.5%.
  • The pharmaceutical sterility testing market was significantly expanding, with a size of USD 1,124.7 million in 2022.
  • By 2033, the pharmaceutical sterility testing industry in China is likely to expand, with a CAGR of 12.1%.
  • By 2033, Australia is projected to expand in the pharmaceutical sterility testing business, with an expected CAGR of 10.4%.
  • The market is expected to grow to USD 1,747. 75 million valuations by 2026, with rising automated techniques.
  • By 2033, India is projected to expand significantly in the pharmaceutical sterility testing sector, with a share of 12.8%.
  • Japan’s pharmaceutical sterility testing industry share expanded significantly, with a 5.1% share in 2022.
  • In 2022, the outsourced segment dominated the market with a share of 54.1%. It is anticipated to control the market by 2033 in terms of services.
  • Based on product type, kits, and reagents dominated the market with a share of 39.7% in 2022.

Power Your Business Decisions with Insights from Get Full Report Now!

Key Players Operating in the Pharmaceutical Sterility Testing industry:

  • Merck KGaA
  • bioMerieux SA
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International Inc.
  • Others

Recent Developments:

  • In June 2022

For its GMP batches, Berkshire Sterile Manufacturing opened a sterility testing isolator and conducted sterility testing. It provides sterile filling of injectable medications, the bulk of which are undergoing clinical trials or have little commercial need.

STEMart has started conducting thorough sterility and microbial tests for sterile, non-pyrogenic medical equipment.

  • Thermo Fisher Scientific announced plans to build two new sterile filling lines in Singapore in October 2020. To increase capacity for producing and developing vaccines and treatments in the APAC region.

Key Segments:

By Product:

  • Kits and Reagents
  • Instruments

By Application:

  • Sterile Drugs
  • Biologics and Therapeutics
  • Medical Devices

By Test Type:

  • Sterility Testing
    • Membrane Filtration
    • Direct Inoculation
  • Bacterial Endotoxin Testing
  • Rapid Micro Test
  • Container Closure Integrity Testing
  • Electrical Resistance
  • Bioburden Testing
  • ATP Bioluminescence
  • Fluorescent Labeling
  • Others

By Services:

  • In-House
  • Outsourced

By End Use:

  • Compounding Pharmacies
  • Medical Devices Companies
  • Pharmaceutical Companies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Narcolepsy Treatment Industry Poised for Significant Growth, Projected to Reach USD 8,718.3 Million by 2034

The global narcolepsy treatment industry is on track to reach a valuation of USD 5,301.6 million in 2024, with projections indicating a robust growth rate of 5.1% CAGR from 2024 to 2034. By the end of the forecast period, the market is expected to soar to an estimated USD 8,718.3 million. This upward trajectory highlights the growing recognition and management of narcolepsy, a neurological disorder that causes excessive daytime sleepiness.

A surge in the prevalence of contributing factors such as obesity, sleep disorders, and mental health conditions is driving the increasing incidence of narcolepsy. As more individuals seek treatment for these underlying conditions, the demand for narcolepsy therapies is also on the rise.

Pharmaceutical treatments like Modafinil, Sodium Oxybate, and Armodafinil continue to dominate the landscape, alongside non-pharmacological therapies such as CPAP, BPAP, and APAP devices, which are gaining adoption for their effectiveness in managing symptoms. The emergence of advanced diagnostic tools and techniques is further fueling the growth of the treatment-seeking population, enabling better detection and intervention at earlier stages.

However, while some medications used in narcolepsy treatment offer relief, their side effects present a challenge for patients and healthcare providers alike. This opens up opportunities for market innovation, particularly in the development of new therapies that minimize adverse effects while improving efficacy.

Moreover, ongoing education programs and awareness campaigns aimed at both the general public and healthcare professionals are playing a crucial role in encouraging the adoption of narcolepsy treatments. These initiatives have significantly increased awareness of sleep disorders, helping to reduce stigma and ensure patients receive timely care.

As narcolepsy continues to gain attention in the medical community, the market for its treatment is expected to expand, offering new opportunities for both patients and industry players alike.

Key Takeaways:

  • The global Narcolepsy treatment industry is projected to reach USD 5,301.6 million in 2024, with a steady growth rate of 5.1% CAGR from 2024 to 2034.
  • By 2034, the market is expected to achieve a value of USD 8,718.3 million.
  • Regional growth trends indicate:
    • The USA will experience a 1.6% CAGR in value from 2024 to 2034.
    • Canada is expected to witness a 2.8% CAGR during the same period.
    • Germany’s market is projected to grow at a 1.6% CAGR.
    • France is anticipated to see a 2.6% CAGR.
    • Spain will experience a 3.0% CAGR.
    • China’s market growth is forecasted at 5.1% CAGR, the highest among major markets.
    • India is expected to lead with a 5.8% CAGR.
    • Japan’s market is projected to grow at a 2.1% CAGR.

Enhanced Market Demand: Discover Thorough Trends and Insights in Our Complete Report!

Competitive Landscape of the Narcolepsy Treatment Industry:

Market participants are focusing on research and development to innovate new drugs and treatments that could provide a competitive edge. Companies in the narcolepsy treatment industry are at various stages of drug development.

Some are in the early stages, investigating new lead molecules, while others are advancing through clinical trials, having completed Phase 2 and moving into Phase 3. There are also companies that have completed their clinical trials and are preparing for product launches following FDA approval. This dynamic landscape contributes to a positive growth outlook for the market in the coming years.

Recent Industry Developments in the Narcolepsy Treatment Market:

  • October 2024: Avadel Pharmaceuticals Plc announced the FDA approval of its supplemental new drug application for LUMRYZ, a sodium oxybate ER oral suspension for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 years and older.
  • April 2024: Harmony Biosciences Holdings, Inc. launched a global Phase 3 registrational trial for the TEMPO study to evaluate the safety and efficacy of Pitolisant, a treatment for EDS and other behavioral symptoms in patients with Prader-Willi syndrome (PWS) aged 6 years and older.
  • February 2024: Takeda announced plans to initiate a Phase 3 clinical trial to assess TAK-861 (oral orexin receptor 2 agonist) in patients with narcolepsy type 1.

Key Players of the Narcolepsy Treatment Industry:

  • ResMed Inc.
  • Koninklijke Philips N.V.
  • Merck & Co. Inc.
  • Drive DeVilbiss Healthcare LLC
  • GlaxoSmithKline Plc.
  • Fisher & Paykel Healthcare Limited
  • Pfizer Inc.

Narcolepsy Treatment Market Segmentation

By Product:

In terms of products, the industry is bifurcated into narcolepsy treatment drugs (Modafinil, Sodium Oxybate, Armodafinil, and others) and devices (CPAP devices, BiPAP devices, and APAP devices)

By Distribution Channel:

In terms of distribution channel, the industry is segregated into hospital pharmacies, retail pharmacies, e-commerce, drug stores, and others.

By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, the Middle East, and Africa have been covered in the report.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Breast Cancer Screening Tests Industry Poised to reaching USD 4.4 Billion by 2033, Driven by Innovative Imaging Technologies

The global breast cancer screening tests industry, valued at USD 2.1 billion in 2023, is set to achieve significant growth, reaching USD 4.4 billion by 2033, according to recent market projections. This robust growth trajectory reflects a CAGR of approximately 7.8% over the forecast period (2023–2033).

Globally, digital mammography has supplanted traditional film-based mammography. Digital mammography has advantages such as improved image quality, quicker image storage and retrieval, and the possibility of computer-aided detection (CAD) systems assisting radiologists in interpretation.

Imaging technologies, such as 3D mammography (tomosynthesis), have advanced in the breast cancer screening test market, providing more comprehensive images and reducing false-positive findings. Other developing technologies are being investigated for improved accuracy and patient experience, such as contrast-enhanced mammography and automated breast ultrasonography.

Biomarker testing, in addition to imaging-based screening assays, is significant in breast cancer screening. Biomarkers, such as BRCA gene mutations and specific protein markers (e.g., HER2, hormone receptors), aid in determining a person’s risk of getting breast cancer and guiding treatment recommendations.

Regulatory agencies, such as the United States Food and Drug Administration (FDA), are critical in authorizing and regulating breast cancer screening tests to assure their safety and efficacy. Compliance with regulatory regulations is required for screening test market entry and commercialization.

Key Takeaways from Market Study:

  • Among diagnostic test type, imaging tests accounts for USD 1.1 billion in 2022 owed to its potential for computer-aided detection (CAD) systems to assist radiologists in interpretation.
  • Hospitals held more than 3% of the global market share in 2022. This can be attributed to the fact that the majority of the world’s population suffers from diseases that, with skilled assistance, can be appropriately detected in the hospital setting.
  • By region, North America held dominant share in world in 2022. The U.S. leads in this region with high prevalence of breast cancer and high requirement of breast cancer screening devices.
  • East Asia is set to provide lucrative opportunities for players while growing at an expected growth rate of 5% CAGR over the forecast period.

“The growing cancer burden and increasing adoption of non-invasive treatment contribute to higher demand of breast cancer screening tests.” says an analyst of Future Market Insights.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

Market Competition:

The breast cancer screening test market is highly competitive, with key players including Ion Beam and Sumitomo Heavy Industries. These companies are constantly participating partnerships, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.

  • June, 2023, Heligenics, a cutting-edge biotech startup, has announced the development of a first precise genetic test for choosing among breast cancer medicines.

Key Companies Profiled:

  • AstraZeneca
  • Novartis
  • Sanofi
  • Pfizer
  • Bayer AG
  • GlaxoSmithKline plc
  • Siemens Healthineers
  • Hologic Inc.
  • General Electric Company
  • Koninklijke Philips NV
  • Fujifilm Holdings
  • A&G Pharmaceutical, Inc.
  • Biocrates Life Sciences AG
  • Metabolomic Technologies, Inc.

Key Market Segments Covered in the Breast Cancer Screening Test Industry Research:

By Diagnostics Test Type:

  • Blood Marker Tests
  • Imaging Test
    • Mammography
    • MRI screening test
    • Molecular Breast Imaging Test
    • PET scan
    • Ultrasound
  • Genetic Test
    • Fluorescence In Situ Hybridization
    • HER gene test
  • Immunohistochemistry Test

By End User:

  • Hospitals
  • Diagnostic Centres
  • Cancer Institutes
  • Research Laboratories

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Catheter Industry Poised for Substantial Growth, Projected to Reach USD 23,281.63 million by 2033 witness a CAGR of 6.3%

In 2023, the catheter industry is projected to surge to a size of around USD 12,591.30 million. In the forecast period from 2023 to 2033, it is expected to experience a CAGR of 6.3%.

By 2033, the market for catheters will probably be worth USD 23,281.63 million. It is anticipated that during the assessment period, it will demonstrate a total financial potential worth USD 9,621.3 million.

Cardiac catheters are projected to witness high demand owing to their growing usage in heart treatment procedures like angiograms and angioplasty. They are highly renowned for their ability to reduce infections and complications, making it equally preferred among patients.

The global market for catheters is poised for substantial growth, driven by several factors. These include the increasing prevalence of cardiovascular, neurologic, and urological disorders. A rising preference for minimally invasive procedures, and the growing demand for antimicrobial catheters are also crucial market drivers. Chronic disorders have become a leading cause of mortality and morbidity worldwide, underscoring the market’s significance.

The worldwide demand for catheters is expected to increase due to the rising popularity of minimally invasive surgeries as people prefer less invasive treatments. Leading market participants are also introducing new items to satisfy this need.

A novel coronary drug-coated balloon (DCB) developed for percutaneous coronary intervention (PCI) treatments in patients with coronary artery disease (CAD), is the Prevail DCB catheter. Medtronic plc debuted this product in Europe in July 2021. With the increased popularity of minimally invasive treatments, the introduction of similar products is anticipated to accelerate the use of catheters for the treatment of cardiovascular disease.

Key Takeaways from the Catheter Market Study

  • The global catheter industry stood at a valuation of around USD 11930.3 million in 2022.
  • The hospital segment by end-use is set to showcase a steady CAGR of 7% through 2033.
  • The acute kidney injury segment by indication is estimated to register a significant CAGR of 1% in the forecast period.
  • The intravenous catheters segment by product accounted for a dominant share of 4% in 2022 in the global catheter industry.
  • The United Kingdom is estimated to register an average CAGR of 1% during the forecast period in the catheter industry.

“It is anticipated that catheters would be employed for diagnostic procedures, including hemodialysis and electrophysiological tests. Globally, it is anticipated that there will be an increasing demand for effective medical services due to the rising prevalence of diseases, such as cancer, acute illness, and trauma. To provide appropriate care, it is expected that medical practitioners will use peripherally inserted central catheters (PICC) more frequently in hospitals, operating rooms, and emergency departments.” – says an analyst of Future Market Insights (FMI).

Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report!

Competitive Landscape

The improvement of product features is a top priority for leading players in the catheter industry as a way to strengthen their positions. They also want to increase their presence in emerging areas.

Entering into strategic collaborations and agreements with other businesses is a key tactic used by top manufacturers to keep their dominance in the catheter industry. It is predicted that these tactics will aid them in extending the reach of their firm.

For instance,

  • Coloplast introduced the cutting-edge intermittent catheter Luja in February 2023 to address significant UTI risk factors. These place a heavy burden on both people who use intermittent catheters and the healthcare system as a whole. The first and only male catheter with more than 80 micro-holes, Luja, was created to help address severe UTI risk factors related to intermittent catheterization.
  • Cardinal Health and Kinaxis entered into a collaboration agreement in February 2022 to improve the visibility of medical products and the efficiency of the supply chain.

Key Companies Profiled

Becton; Dickinson & Company; Cardinal Health; B. Braun Melsungen AG; Coloplast; Medtronic; ConvaTec Inc.; Teleflex Inc.; Stryker Corporation (Cerus Endovascular); Sterimed Group; VOGT Medical; Optimum Medical Limited; Insung Medical; BACTIGUARD AB; Polymedicure; Utah Medical Products; Inc.; Smiths Medical; Argon Medical Devices; Inc.; Boston Scientific Corporation; Cook Medical Incorporated; Fresenius Kabi AG

Catheter Industry Outlook by Category:

By Product:

  • Urinary Catheters
    • Foley Catheters
    • Intermittent Catheters
    • External Catheters
    • Compact Catheters
  • Intravenous Catheters
    • Peripheral Catheters
      • Short Peripheral IV Catheter
      • Integrated/Closed PIVC
    • Central Venous Catheters
      • Peripherally Inserted Central Catheters (PICC)
      • Implanted Port
      • Tunneled Central Venous Catheters
      • Non-tunneled Central Venous Catheters
  • Hemodialysis Catheters
    • Cuffed Tunneled Catheter
    • Non-cuffed Tunneled Catheters
    • Non-tunneled Catheters

By Indication:

  • Urinary Incontinence
  • Urethral Stricture
  • Chronic Obstruction
  • Neurogenic Bladder
  • Enlarged Prostate Gland/BPH
  • Prostate Cancer
  • Acute Kidney Injury
  • Others

By End-user:

  • Hospitals
  • Dialysis Centers
  • Long-term Care Facilities
  • Ambulatory Surgical Centers
  • Home Care

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Superficial Punctate Keratitis Treatment Industry to reach USD 9.6 billion by 2033; Growing at a 6.33% CAGR: FMI Study

The global superficial punctate keratitis treatment industry is slated to reach a valuation of USD 5.3 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.33% CAGR until 2033, valued at USD 9.6 billion.

The increase in the prevalence of infectious diseases is driving the superficial punctate keratitis treatment industry, where the disease becomes more extensive as soon as the temperature rises. It is also identified that such a type of disease is common in tropical regions, therefore a rise in the global temperature influences the incidence of keratitis, thereby expediting the market.

The global demand for keratitis treatment is being determined by the rise in medical spending. There also have been a few advancements that help in limiting sales growth. With considerable investments, the keratitis treatment industry provides the opportunity for detection of the coronary eye disease by embracing a good perception throughout the coming years. But this disease is also spreading due to the provision of poor sanitary conditions in developing nations.

The disease is transmitted as a result of poor sanitary conditions in developing nations. Although, wearing contact lenses while swimming is another aspect ramping up the contamination of the eye, thus this is also contributing to the contribution of the keratitis treatment.

Recently, intervention in surgery may also be an option for patients with refractory superficial punctate keratitis, not responding to medical treatment, and severe fungal infections. The penetration of keratoplasty is considered to be the most common surgical intervention for serious fungal keratitis and cases with perforation or impending perforation. Modern advances have added more options like targeting the drug delivery at the site of infection in the form of intrastromal injections, collagen cross-linking, and rose Bengal-aided photodynamic therapy.

North America is said to have the dominant share due to the rapid usage of modernization and contact lens, but individuals living in developing countries, specifically in remote regions are said to get more affected because of the lack of access to healthcare providers because of low revenues.

Key Takeaways from the Market Study:

  • Around 3.7 billion people under the age of 50 have Superficial Keratitis.
  • The global superficial punctate keratitis treatment industry grew at a CAGR of 5.56% from 2018 to 2022.
  • PCR is highly sensitive, but a large variation has been observed in numerous studies between the rates of SPK detection by PCR when compared to clinical diagnosis.
  • The treatment of Superficial Punctuate keratitis usually involves medicine, including eye drops or antiviral medications taken by mouth.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Competitive Landscape:

Some of the prominent players in the global market for Nephroblastoma Therapeutics Market treatment are-

  • Dompé Farmaceutici
  • Allergan
  • Bausch Health Companies Inc.
  • CONTACARE
  • OHTO Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Neuroptika
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Grand Pharma Co., Ltd.
  • Zhejiang CONBA Pharmaceutical Co., Ltd.

Some of the important developments of the key players in the market are:

  • In November 2020, Pfizer Inc. completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.
  • In September 2020, Bausch Health Companies Inc. agreed to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics.
  • In August 2016, Allergen plc agreed to acquire ForSight VISIONS, a privately held, clinical-stage biotechnology company focused on eye care, for a USD 95 million upfront payment.

Key Segments Profiled in the Superficial Punctuate Keratitis Market Treatment Report:

By Drug Class:

  • Amphotericin B
  • Griseofulvin
  • Voriconazole

By Route of Administration:

  • Oral
  • Topical

By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Future Market Insights Projects Rapid Growth in USA Medical Coding Industry USD 2.3 Billion by 2033, Driven by AI Integration

Future Market Insights has released a groundbreaking forecast for the USA medical coding industry, predicting significant growth over the next decade. According to the latest report, the market, valued at USD 1.0 billion in 2023, is expected to surge to USD 2.3 billion by 2033, representing a robust Compound Annual Growth Rate (CAGR) of 8.4%. This remarkable growth is primarily attributed to technological advancements, particularly the integration of artificial intelligence (AI) into medical coding processes.

AI is revolutionizing the medical coding landscape by automating the search for accurate codes corresponding to specific medical conditions, significantly improving efficiency and reducing manual workloads. With AI, routine tasks can now be automated, allowing medical coders to focus on analyzing complex patterns in medical data. This shift not only enhances operational efficiency but also improves healthcare quality and safety by enabling professionals to dedicate more time to intricate analytical tasks.

A key driver of this transformation is the use of natural language processing tools embedded in computer-assisted coding (CAC) systems. These advanced systems are capable of analyzing extensive patient data, identifying patterns, and correlating them to appropriate medical codes, thereby streamlining the coding process. This AI-driven innovation helps reduce errors, improve workflow efficiency, and optimize real-time auditing functions.

As healthcare organizations continue to adopt AI-driven tools, the medical coding industry in the USA is poised for a significant shift. The integration of AI is expected to boost operational efficiencies and ensure more accurate coding, which is essential for billing and insurance processes. This technological advancement promises to enhance the management of medical records and billing systems, raising the overall standards of healthcare administration.

Key Takeaways from Market Study:

  • The emergency medicine segment dominated the market in 2022 with a 6% market share due to significant demand for immediate care required for ill and injured patients.
  • In 2022, the outsourced service accounted for 6% of the market share, owing to the benefits that this service provides to medical coding service users.
  • In 2022, the enterprise therapy practices dominated the end user category with a market share of 4% due to growing demand for medical coding solutions and software.
  • Midwest USA topped the list by region, with a market share of 8% in 2022, and is anticipated to remain at the top till the forecast period.

“Increase in the outsourcing of medical coding services and increased advancements in the medical coding field is set to propel the sales of medical coding software and services across the USA  ” according to a researcher of Future Market Insights.

USA Medical Coding Trends Unveiled: Get a Complete Overview with Insights from Our Full Report!

Market Competition:

The developers of medical coding software are expanding the market by introducing new solutions that provide an enhanced level of ease to the users. The companies are focused on increasing recognition and position in the USA market. Their coders usually are American Academy of Professional Coders (AAPC) certified.

  • In 2021, Maverick continued to provide its mCoder deep learning artificial intelligence platform in the USA healthcare business.
  • In order to broaden its product line and provide a neutral, reliable, and pervasive platform for the interchange of data across the healthcare industry, Datavant and Ciox concluded their merger in 2021.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the USA medical coding industry in its latest study, presenting a historical demand assessment of 2015 to 2022 and projections for 2023 to 2033. The USA medical coding market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Companies Profiled:

  • Tebra (Kareo, Inc.)
  • Global Payments, Inc. (AdvancedMD, Inc.)
  • EverCommerce Inc. (DrChrono Inc.)
  • The 3M Company (3M Health Information Systems, Inc.)
  • Greenway Health, LLC
  • Dolbey
  • GeBBS Healthcare Solutions (Aviacode Inc.)
  • AQuity
  • Baruch Business Solutions
  • Infinx
  • athenahealth, Inc.
  • BUDDI.AI
  • Context4 Healthcare, Inc.
  • Eclat Health Solutions Inc.
  • Maverick Medical AI Ltd.
  • UnitedHealth Group Inc. (Optum, Inc.)

Key Segments Covered in USA Medical Coding Industry Research:

Clinical Specialties:

  • Emergency Medicine
  • Diagnostic Pathology Services
  • Diagnostic Imaging
    • Radiology Imaging
    • Interventional Radiology
    • Nuclear Medicine
  • Inpatient Treatment
    • Radiology Imaging
    • Interventional Radiology
    • Nuclear Medicine
    • Anaesthesia and Critical Care
    • Cardiology & Cardiac Surgery
    • Gastroenterology & Hepatology
    • Obstetrics and Gynecology
    • Nephrology
    • Urology
    • Neurology & Neurosurgery
    • General Surgery
    • Orthopedics
    • Spinal and Pulmonology
    • Reproductive Medicine
    • Rheumatology
    • Dental Sciences & Cranio-Maxillo Facial Surgery
    • Oncology
    • Diabetology & Endocrinology
    • Pediatrics & Neonatology
    • Psychiatry & Clinical Psychology
    • Organ Transplant
  • Outpatient Treatment & Diagnostics
  • Ophthalmology
  • Dermatology
  • ENT
  • Clinical Nutrition
  • Ambulatory Surgery
  • Physician Office Visits
  • Ancillary Services
  • Observation Services
  • Others

Service:

  • In-house
  • Outsourced

End User:

  • Enterprise Therapy Practices
    • Hospitals
    • Ambulatory Surgical Centers
    • Cancer Research Institutes
    • Long Term Care Centers
  • Small Therapy Practices
    • Specialty Clinics
    • Independent Physician Practices
  • Diagnostic & Reference Laboratories
  • Diagnostic Imaging Centers
  • Educational & Research Institutes
  • Healthcare Payers
  • EMS Services
  • Health Services

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Birth Tissue Products Industry to Reach USD 4.5 Billion by 2033, Growing at a CAGR of 6.6%

The global birth tissue products industry is on a robust growth trajectory, with a valuation of USD 2.3 billion in 2023. Driven by advancements in regenerative medicine and a growing recognition of the diverse applications of human birth tissues, the market is projected to expand at a compound annual growth rate (CAGR) of 6.6% through 2033, reaching an estimated USD 4.5 billion by the end of the forecasted period.

A recent study by Future Market Insights reveals that amniotic membrane tissue currently holds the largest share in the market, with a substantial 34.2% share as of 2022. Amniotic membrane tissue is highly valued for its unique regenerative properties, making it a key player in various therapeutic and medical applications.

The “birth tissue products industry” encompasses the utilization of human birth tissues, including the placenta and umbilical cord, for the creation of a wide range of products. These products are extensively used in both medical and cosmetic fields, leveraging their regenerative capabilities for enhanced tissue repair, wound healing, and as adjuncts in orthopedic and surgical procedures. Additionally, birth tissue products are increasingly recognized for their ability to modulate the body’s immune response, positioning them as an essential resource for developing advanced treatments for autoimmune and inflammatory diseases.

As the market continues to grow, both the medical and cosmetic industries are witnessing increased interest in the therapeutic potential of birth tissues. Innovations in regenerative medicine, along with rising awareness of the clinical benefits, are expected to further drive demand for birth tissue products in the coming years.

Key Takeaways:

  • The global birth tissue products market was valued at USD 2.3 billion in 2023 and is projected to grow at a CAGR of 6.6%, reaching USD 4.5 billion by 2033.
  • Amniotic membrane tissue led the market in 2022, with a share of 34.2%.
  • The USA dominates the market with a 32.9% market share in 2022 and is expected to continue its growth due to the rising acceptance of regenerative medicine and increasing demand for novel treatments driven by an aging population and chronic diseases.
  • In China, the market holds a 9.2% share and is growing rapidly due to the growing awareness of the benefits of birth tissue products in tissue regeneration and wound healing, as well as the affordability and accessibility of these products.
  • Japan holds a 5.2% share in the global market and is experiencing growth due to the increasing demand for regenerative medicine, technological advancements in tissue engineering, and government support for the development of products for regenerative treatments.
  • India‘s market share is 5.0%, with anticipated high growth driven by increasing public awareness of the healing benefits of birth tissue products and improvements in healthcare infrastructure that make these products more accessible.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Competitive Landscape:

Manufacturers of birth tissue products are increasingly focusing on differentiation through strategies such as market expansion, securing regulatory approvals for additional products, obtaining marketing approvals in new regions, and entering new geographic areas. These efforts are often complemented by partnerships with major global organizations, as well as ongoing research and development initiatives. The market dynamics have evolved due to rising awareness. For example, in November 2018, Organogenesis Inc. launched the Advanced Healing Education Resource Center, a microsite designed for continuing medical education that highlights the latest advancements in wound healing.

  • In January 2023, MIMEDX entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED, a subsidiary of Gunze Limited, to promote the EPIFIX product in Japan.

Key Manufacturers and Suppliers of Birth Tissue Products:

According to FMI analysis are

  • Amiox medical
  • biotissue inc
  • AATB
  • U.S. Stem Cell Inc
  • Vericel Corp. (Aastrom Biosciences Inc.)
  • Organogenesis Inc. (Advanced Biohealing)
  • Cerapedics Inc
  • Mesoblast Ltd.
  • Ocata Therapeutics Inc. (Astellas Pharma Inc.)
  • Tissue Recover(Alpha Cord)
  • BTR(Birth Tissue recovery)LLC
  • Tellagen llc
  • Predictive biotech

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

Key Market Segments Covered in the Birth Tissue Products Industry Research:

Tissue:

  • Placenta
  • Amniotic Membrane
  • Chorionic Membrane
  • Amniotic Fluid
  • Umbilical Cord Tissue
  • Umbilical Veins
  • Wharton’s Jelly

Application:

  • Cardiovascular Disorders
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Care
  • Ophthalmology

End User:

  • Hospitals
  • Birth Centers
  • Academic & Research Institutes

Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global 3D Printing Photopolymers Industry Set for Explosive Growth, Projected to Reach USD 5.0 Billion by 2033

The global 3D printing photopolymers industry is poised for extraordinary growth, with new market analysis forecasting a leap from USD 935.0 million in 2023 to an astounding USD 5.0 billion by 2033. This remarkable expansion represents a compound annual growth rate (CAGR) of 18.3% over the next decade, underscoring the transformative impact of 3D printing technology across various industries.

3D printing, or additive manufacturing, has revolutionized traditional manufacturing methods, offering unprecedented precision, efficiency, and design flexibility. At the heart of this revolution is the 3D Printing Photopolymers industry, which utilizes light-curable materials to produce intricate and complex objects. These advanced materials enable the creation of high-quality products with precise geometries, making them indispensable in industries ranging from healthcare and automotive to aerospace and consumer goods.

This unprecedented growth in the 3D printing photopolymers industry underscores the increasing adoption and integration of 3D printing technologies in various sectors, from healthcare and aerospace to automotive and consumer goods. The ability to create highly detailed and customized products quickly and cost-effectively is driving demand and fostering innovation.

As industries continue to seek more efficient and flexible manufacturing solutions, the role of 3D printing photopolymers is expected to become even more pivotal. This market expansion reflects broader trends in technological advancements and the growing need for sustainable and adaptable manufacturing practices.

Key Takeaways 3D Printing Photopolymers Market:

  • Rapid Growth: The 3D printing photopolymers industry had been experiencing rapid growth due to the increasing adoption of 3D printing technologies across various industries. This growth was primarily driven by the automotive, aerospace, healthcare, and consumer goods sectors.
  • Material Advancements: Significant advancements were being made in 3D printing photopolymer materials, resulting in improved properties such as mechanical strength, durability, and flexibility. This enabled a broader range of applications and expanded the potential uses of 3D printed objects.
  • Customization and Design Flexibility: 3D printing photopolymers offered enhanced design flexibility and the ability to create highly customized products without incurring substantial additional costs. This aspect was especially beneficial for industries like healthcare and aerospace, where personalized and intricate designs were required.
  • Reduced Manufacturing Costs: The use of 3D printing photopolymers allowed for more cost-effective manufacturing processes, particularly for low-volume production runs. This technology was often used to produce complex components and prototypes without the need for expensive tooling.
  • Rise of DLP and SLA Printing: Digital Light Processing (DLP) and Stereolithography (SLA) were the two main 3D printing technologies utilizing photopolymers. These methods enabled faster printing speeds and higher precision compared to some other additive manufacturing techniques.
  • Industry-Specific Solutions: The market saw an increasing trend of companies developing and offering photopolymer materials tailored to specific industries. For instance, there were formulations optimized for dental applications, biocompatible materials for medical use, and high-temperature-resistant polymers for aerospace purposes.

Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!

Competitive Landscape:

  • Bomar
  • Polysciences Inc.
  • Alfa Aesar (Thermo Fisher Scientific Inc.)
  • Inoes
  • Röhm GmbH
  • BASF
  • SOLTECH LTD.
  • Mohini Organics Pvt. Ltd.
  • Fushun Donglian Anxin Chemical Co., Ltd.
  • Gelest Inc.
  • Sinocure Chemical Group
  • Kyoeisha Chemical Co., Ltd
  • AGC
  • Allnex GMBH
  • Evonik
  • Sartomer arkema
  • Miwon

Key Market Segments Covered in the Industry Research:

Material:

  • Polymers
  • Oligomers
  • Monomers
  • Additives

Application:

  • Surgical Models
  • Wearable Biosensors
  • Implants
    • Cardiovascular Implant
    • Orthopaedic Implant
    • Dental Implant
    • Others
  • Customized Prosthetic
  • Exoskeleton
  • Hearing Aids

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Electrosurgery Generator Industry to Surge, Projected to Reach USD 3.4 Billion by 2033: Future Market Insights

The global electrosurgery generator industry is poised for significant growth, with its valuation projected to rise from USD 1.6 billion in 2023 to approximately USD 3.4 billion by 2033, according to a recent study by Future Market Insights. This represents a robust compound annual growth rate (CAGR) of 7.7% over the forecast period.

Changing the electrical current that the electrosurgical generating units (ESU) produce into heat energy within tissue is a process known as electrosurgery. The rise in surgical procedures is one of the key factors anticipated to propel the growth of the market for electrosurgical generator during the forecast period. Demand for minimally invasive procedures as well as the rising ageing population further adds to the growth of the market.

The ability to cut or cauterise tissue with a high-frequency electrical current makes electrosurgical generators (ESG) more and more common. Because it provides surgeons with a precise and controllable energy source during surgery, an ESG is essential. With the help of this electrical energy, the tissue is cut or coagulated. Electrosurgery generator demand is expected to rise due to the demand for least invasive procedures.

Laparotomy, a surgical method used to identify, treat, and stage endometrial cancer, has been replaced by conventional and robot-assisted laparoscopic procedures. The electrosurgical equipment used in laparoscopic operations to treat endometrial cancer has undergone several improvements. Innovations were developed in order to solve the problem of heat damage in the traditional monopolar and bipolar devices. Recently, new products using argon plasma technology have entered the market.

  • The HelixARTM Electrosurgical Generator with Argon Plasma Coagulator Technology, for instance, combines the advantages of CONMED’s most cutting-edge ABC® technology with the improved specialized modes of a high-end ESU.

Key Takeaways from Market Study:

  • Accessories lead the product segment as it held 4% market value share in 2022, owing to their large volume consumption falling under consumables.
  • In specialty segment, gynecology held the largest share of 5% share in global market in 2022 as it has the highest available products in the market and is the most used application for minimally invasive procedures.
  • By end user, hospitals held a share of around 5% in 2022 due to the high number of surgical procedures conducted in them.
  • North America held a value share of around 2% in 2022, having the highest adoption of electrosurgical generators and investments in research and development.

“The market for electrosurgery generators is expected to expand globally in light of the technologically advanced products that cater to all the safety standards of minimally invasive procedures,” says an analyst of Future Market Insights.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Market Competition:

The major companies in the industry are consciously extending the range of products and services they can provide. The market has seen significant consolidation. Many multinational corporations are purchasing local competitors. The market’s participants are concentrating on creating and releasing technologically advanced items that are also reasonably priced.

  • Symmetry Surgical (“Symmetry”) was acquired by Aspen Surgical Products, Inc. in October 2022 from RoundTable Healthcare Partners.
  • Enseal X1 Straight Jaw Tissue Sealer, which offers better sealing, more efficiency, and easier access to target tissue during various surgical operations, was introduced by Ethicon in April 2022.

Key Companies Profiled:

Medtronic Plc.; Ackermann Instrumente; B. Braun Melsungen AG; JINSHAN Science & Technology (Group) Co., Ltd.; Symmetry Surgical Inc. (Aspen Surgical ); Miconvey SURGICAL; Telea Electronic Engineering S.r.l.; Olympus Corporation; Ethicon US, LLC.; MEDGYN PRODUCTS, INC.; Integra LifeSciences; CONMED Corporation; EMED.; Erbe Elektromedizin GmbH; Beijing Kestrel Co., Ltd.; Matrix Medicals Pvt. Ltd.; Shanghai Huifeng Medical Instrument Co., Ltd; Zimmer Biomet; Micromed Medizintechnik; Heal Force, Promed Technology Co.; KENTAMED Ltd.; TAKTVOLL Co.,Ltd; Senko Medical Instrument Mfg. Co., Ltd.

Key Market Segments Covered in Electrosurgery Generators Industry Research:

By Product:

  • Radiofrequency Electrosurgery Generators
  • Ultrasonic Electrosurgery Generators
  • Molecular Resonance Electrosurgery Generators
  • Argon Plasma Electrosurgery Generators
  • Accessories

By Specialty:

  • Urology
  • Gynecology
  • Gastroenterology
  • ENT
  • General Surgery
  • Others

By Settings:

  • Hospitals
    • Academic
    • Community
    • Private
  • Ambulatory Surgical Centres
  • Speciality Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube